Halozyme Therapeutics Inc is a biopharmaceutical company that specializes in developing and commercializing innovative enzyme-based therapies. Utilizing its patented recombinant human hyaluronidase enzyme (rHuPH20), Halozyme enhances the delivery of injectable biologics, including monoclonal antibodies and other therapeutic molecules. Its product lineup addresses a variety of medical conditions, from hydration and drug dispersion to treating chronic diseases such as HIV, multiple sclerosis, and various cancers. Founded in 1998, Halozyme is headquartered in San Diego, California, serving a global market.
Live Updates No updates were posted during this live coverage. Here are a few recent upgrades you may want to pay attention to. Palantir Technologies Palantir Technologies (NYSE: PLTR | PLTR Price…
Investing in biotech stocks can be rewarding. Not just because these stocks have the potential to produce meaningful gains in your portfolio, but also because when you invest in them, you’re investing…
Thursday's top analyst upgrades and downgrades included Airbnb, Alcon, Antero Midstream, Exact Sciences, GitLab, GlobalFoundries, Halozyme Therapeutics, Lumentum, Nektar Therapeutics, PayPal and Southern Copper.
Monday’s top analyst upgrades and downgrades included Chipotle Mexican Grill, CRISPR, Hess Midstream, iMedia Brands, Kinder Morgan, Wendy’s and more.
Monday's top analyst upgrades and downgrades included Foot Locker, Halozyme Therapeutics, Kimberley-Clark, Occidental Petroleum, Texas Roadhouse, Trip.com and Williams Companies.
Thursday's top analyst upgrades and downgrades included Alphabet, Chevron, Citigroup, Facebook, Fastly, Paypal, Snap, Twitter and Under Armour.
The top analyst upgrades, downgrades and initiations seen on Thursday include Aetna, Analog Devices, Lowe's, Merck, Pfizer, Plug Power, Qualcomm and Target.
With 2017 nearing an end, it is important to consider just what has happened. 24/7 Wall St. has screened 50 stocks that have risen 100% or more (some far more) in 2017.
Halozyme Therapeutics saw its shares make a handy gain early on Thursday after the firm announced that it licensed its Enhanze drug-delivery technology to Roche for exclusive development of an “undisclosed therapeutic…
Chris Lange As the markets are continuing to heat up, a few biopharma stocks made massive gains on Thursday. There is a very positive sentiment in the health care sector in anticipation of the…
Over the past week, Halozyme Therapeutics and a couple of other biotech companies made impressive runs.
These biotech companies stood out from the rest with big moves over the course of the past week.
Halozyme Therapeutics hit a new 52-week low in Monday's session following the release of a business update at JPMorgan’s 34th Annual Healthcare Conference.
Chris Lange Halozyme Therapeutics has announced a global collaboration and license agreement with AbbVie.
Many investors are looking for where to put their money now that the Dow Jones Industrial Average has hit 18,000.
